Open AccessCosts and Healthcare Resource Utilization Associated with Idarucizumab or Andexanet Alfa Oral Anticoagulant Reversal in Patients Hospitalized with Life-Threatening Bleeds
Clinical And Applied Thrombosis/hemostasisPeer ReviewedAlex C. Spyropoulos +62022Journals
The content you want is available to Zendy users.
Already have an account? Sign inHaving issues? Contact support